Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells-Reference-Cited by-同舟云学术

Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells

Published:2018-08 Issue: Volume:430 Page:34-46
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Krüger Katharina,Geist Katharina,Stuhldreier Fabian,Schumacher Lena,Blümel Lena,Remke Marc,Wesselborg Sebastian,Stork Björn,Klöcker Nicolaj,Bormann Stefanie,Roos Wynand P.,Honnen Sebastian,Fritz Gerhard^ORCID

Funder

the Duesseldorf School of Oncology (Medical Faculty of the Heinrich Heine University Düsseldorf, Germany)

CGC

NIH

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference84 articles.

1. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification;Polkinghorn;Nat. Clin. Pract. Oncol.,2007

2. A clinicobiological model predicting survival in medulloblastoma;Ray;Clin. Canc. Res.,2004

3. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma;Packer;J. Clin. Oncol.,2006

4. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective;de Bont;Neuro Oncol.,2008

5. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study;Ris;J. Clin. Oncol.,2001

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse;International Journal of Cancer;2024-09-06

2. The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells;Biochemical Pharmacology;2023-08

3. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario;Pharmaceutics;2023-02-16

4. Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma;Molecular Cancer Therapeutics;2022-06-16

5. Medulloblastoma and the DNA Damage Response;Frontiers in Oncology;2022-06-07